What is the price target for HRTX stock?
9 analysts have analysed HRTX and the average price target is 4.42 USD. This implies a price increase of 445.68% is expected in the next year compared to the current price of 0.81.
HERON THERAPEUTICS INC (HRTX) Forecast, Price Target & Analyst Ratings
NASDAQ:HRTX • US4277461020
Current stock price
0.81 USD
+0.01 (+1.25%)
At close:
0.8105 USD
+0 (+0.06%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HERON THERAPEUTICS INC (HRTX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.01
- Revenue Estimate
- 40.069M
Price Target Details & History
Consensus Price Target and Range
Mean target
$4.42
Upside
+ 445.67%
From current price of $0.81 to mean target of $4.42, Based on 9 analyst forecasts
Low
$3.03
Median
$4.08
High
$6.30
Price Target Revisions
1 Month
0.00%
3 Months
-3.70%
Price Target Summary
9 Wall Street analysts provided a forecast for the next 12 months for HRTX. The average price target is 4.42 USD. This implies a price increase of 445.68% is expected in the next year compared to the current price of 0.81.
The average price target has been revised downward by 3.7% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.22%
HRTX was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about HRTX.
In the previous month the buy percentage consensus was at a similar level.
HRTX was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-08 | Needham | Maintains | Buy -> Buy |
| 2025-06-09 | HC Wainwright & Co. | Initiate | Buy |
| 2025-04-11 | Needham | Reiterate | Buy -> Buy |
| 2025-02-28 | Needham | Reiterate | Buy -> Buy |
| 2024-12-04 | Needham | Reiterate | Buy -> Buy |
| 2024-11-13 | Needham | Maintains | Buy -> Buy |
| 2024-09-25 | Needham | Reiterate | Buy -> Buy |
| 2024-08-07 | Needham | Reiterate | Buy -> Buy |
| 2024-06-13 | Rodman & Renshaw | Initiate | Buy |
| 2024-05-16 | Needham | Reiterate | Buy -> Buy |
| 2024-05-08 | Needham | Reiterate | Buy -> Buy |
| 2024-04-23 | Capital One | Initiate | Overweight |
| 2024-04-11 | Needham | Reiterate | Buy -> Buy |
| 2024-03-13 | Needham | Maintains | Buy -> Buy |
| 2023-11-15 | Needham | Maintains | Buy -> Buy |
| 2023-08-15 | Needham | Reiterate | Buy -> Buy |
| 2023-07-25 | Needham | Maintains | Buy -> Buy |
| 2023-05-12 | Needham | Maintains | Buy -> Buy |
| 2023-04-21 | Needham | Reiterate | Buy |
| 2023-03-24 | Needham | Maintains | Buy |
| 2023-03-24 | Evercore ISI Group | Maintains | Outperform |
| 2022-11-09 | Needham | Maintains | Buy |
| 2022-06-30 | Needham | Maintains | Buy |
| 2022-05-10 | Needham | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.01
- Revenue Estimate
- 40.069M
- Revenue Q2Q
- 3.00%
- EPS Q2Q
- -151.00%
- Number of Analysts
- 5
Next Earnings Revisions
Revenue (1 Month)
-2.08%
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
N/A
Next Earnings Summary
HRTX is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -0.01 USD and the consensus revenue estimate is 40.07M USD.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 127.044M 17.96% | 144.285M 13.57% | 154.904M 7.36% | 178.57M 15.28% | 214.81M 20.29% | 259.23M 20.68% | 301.77M 16.41% | 335.58M 11.20% | 310.18M -7.57% | 317.83M 2.47% | 314.06M -1.19% | |
| EBITDA YoY % growth | -107.716M 37.31% | -9.036M 91.61% | -224K 97.52% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -110.615M 36.68% | -11.528M 89.58% | -2.538M 77.98% | 5.355M 310.99% | 32.079M 499.05% | 65.28M 103.50% | 95.013M 45.55% | 118.27M 24.48% | 97.92M -17.21% | 102.2M 4.37% | 98.124M -3.99% | |
| Operating Margin | -87.07% | -7.99% | -1.64% | 3.00% | 14.93% | 25.18% | 31.49% | 35.24% | 31.57% | 32.16% | 31.24% | |
| EPS YoY % growth | -0.86 50.29% | -0.09 89.53% | -0.07 22.22% | 0.00 100.00% | 0.12 | 0.22 80.34% | 0.41 91.94% | 0.48 17.28% | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.01 -151.00% | 0.00 100.00% | 0.00 100.00% | 0.01 125.50% |
| Revenue Q2Q % growth | 40.069M 3.00% | 43.588M 17.17% | 45.968M 20.29% | 49.011M 20.75% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -178.5K -105.66% | 1.139M 169.58% | 1.726M 142.17% | 2.737M 7,102.63% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
71.84%
EPS Next 5 Year
54.91%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
18.21%
Revenue Next 5 Year
16.41%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
HERON THERAPEUTICS INC / HRTX Forecast FAQ
What is the next earnings date for HRTX stock?
HERON THERAPEUTICS INC (HRTX) will report earnings on 2026-05-04.
What are the consensus estimates for HERON THERAPEUTICS INC (HRTX) next earnings?
The consensus EPS estimate for the next earnings of HERON THERAPEUTICS INC (HRTX) is -0.01 USD and the consensus revenue estimate is 40.07M USD.
What is the consensus rating for HRTX stock?
The consensus rating for HERON THERAPEUTICS INC (HRTX) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.